Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | CD274 positive |
| Therapy | KN046 |
| Indication/Tumor Type | Advanced Solid Tumor |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| CD274 positive | Advanced Solid Tumor | predicted - sensitive | KN046 | Phase I | Actionable | In a Phase I trial, KN046 treatment was well tolerated and resulted in an objective response rate of 12.5% (11/88; all partial responses) and median duration of response of 16.6 months in patients with advanced solid tumors, patients with CD274 (PD-L1)-positive tumors experienced longer median progression-free survival (2.5 vs 1.3 months, p=0.0098) and overall survival (19.9 vs 5.4 months, p=0.014) than those with CD274 (PD-L1)-negative tumors ( (PMID: 37263673; NCT03733951). | 37263673 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (37263673) | Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4 in patients with advanced solid tumors. | Full reference... |